NewEdge Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11
| Closed | -$83 | – | 3995 |
|
|
2025
Q1 | $83 | Hold |
11
| – | – | ﹤0.01% | 3833 |
|
|
2024
Q4 | $83 | Buy |
+11
| New | +$83 | ﹤0.01% | 3790 |
|
|
2023
Q4 | – | Sell |
-30
| Closed | -$212 | – | 3759 |
|
|
2023
Q3 | $212 | Hold |
30
| – | – | ﹤0.01% | 3320 |
|
|
2023
Q2 | $211 | Sell |
30
-4,078
| -99% | -$28.7K | ﹤0.01% | 3381 |
|
|
2023
Q1 | $34.3K | Sell |
4,108
-4,217
| -51% | -$35.2K | ﹤0.01% | 2154 |
|
|
2022
Q4 | $96 | Buy |
+8,325
| New | +$96 | ﹤0.01% | 3380 |
|
|
2022
Q2 | – | Sell |
-11,495
| Closed | -$187K | – | 1563 |
|
|
2022
Q1 | $187K | Sell |
11,495
-1,123
| -9% | -$18.3K | ﹤0.01% | 1022 |
|
|
2021
Q4 | $175K | Sell |
12,618
-1,637
| -11% | -$22.7K | ﹤0.01% | 1538 |
|
|
2021
Q3 | $205K | Buy |
14,255
+1,964
| +16% | +$28.2K | 0.01% | 1047 |
|
|
2021
Q2 | $194K | Sell |
12,291
-115
| -0.9% | -$1.82K | 0.01% | 1056 |
|
|
2021
Q1 | $126K | Buy |
+12,406
| New | +$126K | ﹤0.01% | 976 |
|
|
2020
Q4 | – | Sell |
-24,000
| Closed | -$82K | – | 981 |
|
|
2020
Q3 | $82K | Buy |
+24,000
| New | +$82K | ﹤0.01% | 875 |
|